Bio Green Med Solution Inc. (BGMS), formerly Cyclacel Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company developing mechanism-driven therapies for cancer and other serious diseases. BGMS leverages expertise in cell-cycle control, transcriptional regulation, epigenetics, and mitosis to advance targeted programs in oncology and hematology, with an emphasis on convenient oral medicines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on developing novel, mechanism-targeted cell cycle drugs designed to be highly selective, potentially inducing death in cancer cells while sparing most normal cells. The company's R&D initiatives include the development of anticancer drug candidates targeting all phases of the cell cycle, with a particular focus on Polo-like Kinase (PLK) inhibitors and Cyclin-dependent Kinase (CDK) inhibitors. The lead drug in the anti-mitotic program is plogosertib, a selective PLK1 inhibitor, which is being developed for solid tumor and hematological malignancy indications. The company is also working on fadraciclib, a CDK2 and CDK9 inhibitor, as part of its transcriptional regulation program. As of December 31, 2024, the company owned two patents granted in the US, two granted by the European Patent Office (EPO), and six granted in other countries worldwide. Additionally, the company held two patent applications filed in the US, two filed at the EPO, and 16 filed in other countries worldwide. In FY2025, the company spent US$0.6 million on its R&D activities.